CL2023002216A1 - Composición farmacéutica que comprende un derivado de difenilpirazina - Google Patents

Composición farmacéutica que comprende un derivado de difenilpirazina

Info

Publication number
CL2023002216A1
CL2023002216A1 CL2023002216A CL2023002216A CL2023002216A1 CL 2023002216 A1 CL2023002216 A1 CL 2023002216A1 CL 2023002216 A CL2023002216 A CL 2023002216A CL 2023002216 A CL2023002216 A CL 2023002216A CL 2023002216 A1 CL2023002216 A1 CL 2023002216A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
diphenylpyrazine derivative
diphenylpyrazine
derivative
diphenylpyrazin
Prior art date
Application number
CL2023002216A
Other languages
English (en)
Inventor
Amssoms Katie
De Proost Eddy
Dong Wenyu
HARTMAN KOK Paul
Holm Rene
Kimpe Kristof
Meurs Greet
Verstraeten Maxim
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2023002216A1 publication Critical patent/CL2023002216A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende calcio; 4-5,6-difenilpirazin-2-il propan-2-il amino butoxi acetato, en particular a inyectables de acción prolongada que comprenden el mismo, el uso de la composición farmacéutica para el tratamiento o prevención de enfermedades específicas, y un proceso para producirlo.
CL2023002216A 2021-01-29 2023-07-27 Composición farmacéutica que comprende un derivado de difenilpirazina CL2023002216A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2021052208 2021-01-29
EP2021082830 2021-11-24

Publications (1)

Publication Number Publication Date
CL2023002216A1 true CL2023002216A1 (es) 2024-03-01

Family

ID=80445780

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002216A CL2023002216A1 (es) 2021-01-29 2023-07-27 Composición farmacéutica que comprende un derivado de difenilpirazina

Country Status (12)

Country Link
US (2) US20240091223A1 (es)
EP (1) EP4284334A1 (es)
JP (1) JP2024508377A (es)
KR (1) KR20230137312A (es)
AU (1) AU2022214282A1 (es)
CA (1) CA3206133A1 (es)
CL (1) CL2023002216A1 (es)
CO (1) CO2023010010A2 (es)
IL (1) IL304525A (es)
MX (1) MX2023008923A (es)
TW (1) TW202239408A (es)
WO (1) WO2022162158A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2023238952A1 (ja) * 2022-06-10 2023-12-14 日本新薬株式会社 医薬組成物
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2005014030A1 (en) * 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
BRPI0908491A2 (pt) 2008-02-28 2015-08-11 Nippon Shinyaku Co Ltd Inibidor de fibrose
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 ***不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
CA2728089C (en) 2008-06-23 2017-04-11 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
SI2289518T1 (sl) 2008-06-23 2017-02-28 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za vnetno črevesno bolezen
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
WO2014069401A1 (ja) * 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
EP3658134A4 (en) 2017-07-24 2021-05-05 Pharmosa Biopharm Inc. LIPOSOME COMPOSITIONS CONTAINING LOW ACID MEDICINAL PRODUCTS AND USES THEREOF
US20210113464A1 (en) 2017-11-27 2021-04-22 Osaka University Disease-site-specific liposomal formulation
JP7032732B2 (ja) 2018-03-01 2022-03-09 国立大学法人 東京大学 プラテンシマイシンの製造方法
WO2020249602A1 (en) * 2019-06-11 2020-12-17 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
EP4021896A4 (en) * 2019-08-19 2023-08-23 Nippon Shinyaku Co., Ltd. SALT

Also Published As

Publication number Publication date
AU2022214282A1 (en) 2023-08-10
MX2023008923A (es) 2023-08-10
IL304525A (en) 2023-09-01
EP4284334A1 (en) 2023-12-06
KR20230137312A (ko) 2023-10-04
JP2024508377A (ja) 2024-02-27
WO2022162158A1 (en) 2022-08-04
TW202239408A (zh) 2022-10-16
CO2023010010A2 (es) 2023-08-09
US20240216366A1 (en) 2024-07-04
US20240091223A1 (en) 2024-03-21
CA3206133A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
CL2023002216A1 (es) Composición farmacéutica que comprende un derivado de difenilpirazina
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
UY33479A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento
AR050717A1 (es) Composiciones farmaceuticas
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
CL2011001363A1 (es) Proceso para la preparacion de un compuesto derivado de etorfina; compuesto derivado de etorfina; composicion farmaceutica que lo comprende; uso del compuesto como analgesico en el tratamiento del dolor.
CL2018001161A1 (es) Composición dermocosmética, proceso de producción de la composición tópica, método para el fortalecimiento de uñas frágiles y uso de la composición
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung
ECSP22050840A (es) Nuevos compuestos farmac?uticos
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
UY27733A1 (es) Derivados de ciclopenteno.
MX2020003660A (es) Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
BR112022016405A2 (pt) Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento
BR112017005241A2 (pt) composto, e, composição farmacêutica.
JOP20220045A1 (ar) تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos
CO2019000942A2 (es) Composición y uso de un péptido
AR058282A1 (es) Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b
DOP2013000144A (es) Combinacion y composicion para el tratamiento de obesidad
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
TR201717703A2 (tr) Api̇ksaban formülasyonlari